A Major Milestone in the Medical Tech Industry
Amber Therapeutics recently completed its Series A fundraising totaling $100 million to continue developing a closed-loop neuromodulation therapy system to treat mixed urinary incontinence. The completion of their series A round will facilitate raising additional funds for future growth, as demonstrated by their presentations at LSI Europe 2024 discussing several concepts that are key to successful fundraising options; examples include the need for founder/investor alignment, strategic decision-making, early clinical validation, and how these factors are critical to creating a framework for medtech startups to obtain large amounts of capital despite challenging financial environments.
According to Aidan Crawley, co-founder and CEO, Amber is uniquely positioned within the medtech space compared to other innovators and investors based on a combination of speed of product development, innovation, and effective execution.
From MVP to Early Clinical Validation
Technical validation of developed technologies at Amber Therapeutics has allowed for ongoing rapid development of neuromodulation hardware with minimal investment. They have taken advantage of existing, proven neuromodulation systems from prior studies and used them to conduct validation of their therapies quickly. This resulted in the first implantation being performed in 18 months and at a significantly lower amount of funding than previously anticipated.
Thus, Amber’s ability to provide validation early in product development has addressed one of the medical device industry’s biggest challenges: long and costly development cycles. In addition, this model of product development has increased confidence among investors and credibility within the European medical device community.
To summarize, medical device innovators can save time (and potentially reduce their regulatory risk) by using existing technology to validate an entirely new device (based upon its design only). By taking advantage of an already developed and accepted technology, the medical devices will be created in a much more expedited manner, as there will be less time spent designing and developing the technologies and/or conducting regulatory submissions for the new products.
The Long-Term Vision Behind the Series A
Amber Therapeutics transitioned toward a more vertically integrated model when it acquired the device company that provided the hardware systems for their lines. This acquisition provided a much greater degree of control over their entire technology stack, created efficiencies throughout the development of new products, and positioned the company more favorably as they prepared for their Series A fundraising. U.S. and Canada-based investors have helped the company complete its long-term plan by providing strong investor support in the stage prior to Series A financing.
As a result of addressing a significant unmet healthcare need, this round of funding attracted a wide range of major and strategic investors. Millions of people worldwide suffer from mixed urinary incontinence, and there are very few available therapies to treat that condition.
There are many investors that focus on medical devices that invest in Amber because investors see a large opportunity both clinically and commercially with this scalable platform.
Strategic Capital and Investor-Founder Alignment
One of the main themes addressed throughout the conference was the value of strategic capital. In addition to providing funding, investors also bring their unique perspectives and knowledge of the industry to play a role in providing guidance to companies as they grow over the long term.
Investors who supported strategic investments were very focused on the following three areas: product-market fit, reimbursement, and trends in healthcare adoption. As these three areas are increasingly important for medtech companies, they also represent areas that will contribute to commercial success (beyond just technology innovation).
The panel discussion by participants in the LSI Europe makes clear that successful partnerships require alignment between partners’ visions, expectations, and plans to execute them. While financing can create a lot of visibility and generate news, how effectively companies use the capital provided will determine whether or not they will achieve their clinical and commercial goals.
Maintaining Momentum After the Raise
The challenge starts after the funding round closes. Raising $100 million was a huge feat, and the panelists all agreed that the true test lies in securing enough resources to support the growth of a business during this time period.
As Med Tech startups expand, they encounter new challenges related to scaling operations, ensuring clinical validation, maintaining culture, and executing on results. Staying committed to executing on growth opportunities will be the company’s primary focus, according to Crawley.
For Amber Therapeutics, focusing on clinical advancements, product innovations, and demonstrating the long-term value of their products in the healthcare marketplace will be key as they begin their next phase of business operations. Throughout their discussions, both investment and leadership groups expressed that sustained momentum will be the largest factor influencing success within the medical technology sector.
Why Amber Therapeutics’ Series A Stands Out
Amber Therapeutics has completed its Series A funding round successfully; however, this is not just an announcement of an investment but rather an illustration of ways that MedTech innovators can leverage strong clinical focus, capital efficiency, and strategic partnerships with investors to expedite growth.
This journey through Amber also illustrates larger trends that are changing the medical technology sector today, as investors are now placing greater emphasis on solid leadership, fast-tracking validation, scalable technologies, and obvious market opportunities.
The LSI Europe event has confirmed that many successful partnerships in the MedTech area have been based on shared values, trust between parties (i.e., timing), and a mutual approach toward solving critical problems in healthcare.
About the Author
